Editor’s note: The archived video recording is embedded below.
The need to respond to the coronavirus pandemic is forcing technology-enabled change in health care at an unprecedented speed. Barriers that have existed for years — whether regulatory, logistical, or scientific — are falling. Join STAT for a four-part digital event series jointly developed and delivered by Harvard Medical School to discuss everything from the rapid deployment of telehealth to the development of drugs and vaccines.
This series will take place on Zoom, and attendees will be able to both see the discussions live and participate by asking questions. Access to the event is free. Access to the Zoom platform is limited to the first 1,000 attendees; any additional attendees will be able to watch the conversation in real time via a livestream on STAT’s website.
Part 1: New biopharma collaborative models for Covid-19. May 7 at 2:30 p.m. ET
- Jay Bradner, M.D., president, Novartis Institutes for BioMedical Research (NIBR)
- Andrew Plump, M.D., Ph.D., president, research and development, Takeda Pharmaceutical
- Rebecca Robbins, San Francisco correspondent, STAT
- Stanley Y. Shaw, M.D., Ph.D., associate dean for executive education, Harvard Medical School